Synovial Sarcoma

What synovial sarcoma is — in plain words

The name is misleading. "Synovial" sarcoma was named more than a century ago because, under the early microscopes of the time, the tumour cells looked a little like the cells that line a joint (the synovium). Modern science has shown that synovial sarcoma does not actually arise from synovial tissue. The name has stuck, but the disease is something quite distinct.

What defines synovial sarcoma today is a specific genetic event: a swap of pieces between two chromosomes that fuses parts of two genes — SS18 and one of the SSX genes — into a single abnormal gene. That fusion is found in essentially every synovial sarcoma, and finding it on a biopsy confirms the diagnosis with a level of certainty that older sarcomas never had.

Synovial sarcoma belongs to the wider family of soft-tissue sarcomas and is best looked after by a sarcoma multidisciplinary team from the very first decision.

Who gets synovial sarcoma — and where

Two features stand out:

• Age. Synovial sarcoma is one of the few cancers that disproportionately affects young adults — most patients are between 15 and 40 years old at diagnosis, with a median age in the early thirties. It does occur in older adults and occasionally in children, but the typical patient is much younger than for most cancers.
• Location. About 70% of synovial sarcomas arise in the limbs — most commonly near a joint, especially around the knee, the ankle, the foot, the shoulder, or the elbow. (This is where the misleading name came from.) The other 30% can occur almost anywhere — in the head and neck, the chest wall, the lung, the abdominal wall, or the retroperitoneum.

There is no strong known cause for most cases. It is not inherited in the usual sense. It is no one's fault.

Signs and symptoms to take seriously

The combination of a young patient, a deep lump near a joint, and persistent pain should never be dismissed as a sprain or a simple cyst without imaging.

"The hardest conversations I have are with young patients whose lump was watched for a year — physiotherapy, painkillers, reassurance — before anyone scanned it. An MRI takes thirty minutes and changes everything. For a deep, persistent lump in a young adult, that is the right next step, not the last one."

How synovial sarcoma is diagnosed

The workup follows the disciplined sequence used for any soft-tissue sarcoma, with one important addition — molecular testing for the SS18-SSX fusion.

• MRI of the primary site — the best scan for showing the size of the tumour and its relationship to muscles, nerves, vessels, and the nearby joint. Synovial sarcoma often has features on MRI that suggest the diagnosis even before biopsy — calcifications within the tumour are a recognised clue.
• CT scan of the chest — the lung is by far the most common site for synovial sarcoma to spread to, and a CT chest is part of staging for every patient. A PET-CT is sometimes added for high-grade tumours.
• Image-guided core-needle biopsy — planned along a path that the surgeon will later remove. Open biopsy in a non-specialist centre can spread tumour along tissue planes and force a much bigger operation later, so this step needs to be done in the right place.
• Specialist sarcoma pathology with molecular testing — the biopsy is examined by a sarcoma-experienced pathologist, and a molecular test is done to look for the SS18-SSX fusion. A positive test confirms the diagnosis with very high certainty.

How we treat synovial sarcoma

Synovial sarcoma is treated aggressively, because it is an aggressive disease — but it also rewards aggressive treatment more than most sarcomas, because it is one of the more chemosensitive subtypes. Treatment is always a multidisciplinary decision, involving a sarcoma surgeon, a medical oncologist, a radiation oncologist, a pathologist, and a radiologist.

Surgery — wide excision with negative margins

For nearly every localised synovial sarcoma, surgery is the central treatment. The aim is a wide excision with clear margins — removing the tumour together with a cuff of normal tissue around it, so no cancer cells are left behind. In the limbs, modern surgery is almost always limb-sparing; amputation is now a rare exception, reserved for the most extreme cases where critical structures cannot be preserved.

Radiation therapy

Radiation is almost always added to surgery for synovial sarcoma — either before the operation (smaller field, lower total dose) or after (larger field, higher total dose). The choice depends on the tumour and the team. Radiation reduces the chance of local recurrence substantially and is part of the standard plan for most patients.

Chemotherapy

Synovial sarcoma is one of the more chemosensitive soft-tissue sarcomas, and chemotherapy plays a real role — particularly for high-grade tumours, large tumours, or tumours in young patients where the risk of micrometastatic spread is highest. The standard combination is ifosfamide with doxorubicin, given for several cycles before and/or after surgery. The treatment is intense but well defined, and most young patients tolerate it well. Read more about chemotherapy →

Immunotherapy and engineered cell therapy — a real breakthrough

For advanced synovial sarcoma — disease that has spread or come back after standard treatment — a remarkable new option has recently become available: an engineered T-cell therapy that targets a protein called MAGE-A4, which is expressed on many synovial sarcoma cells. The treatment, known as afami-cel (afamitresgene autoleucel), involves removing some of the patient's own T cells, engineering them in the laboratory to recognise MAGE-A4, growing them up in large numbers, and infusing them back. In carefully selected patients, this therapy has produced lasting responses where standard chemotherapy had stopped working.

Afami-cel is only available at a handful of specialised centres, requires specific tissue typing (HLA-A*02) and MAGE-A4 expression on the tumour, and is given as part of a comprehensive supportive care plan. But for the right patient, it represents a genuine leap forward — and it is the first cell therapy of its kind approved for any solid tumour. We routinely discuss eligibility for this and other novel therapies for patients with advanced synovial sarcoma. Read more about immunotherapy →

What the outlook honestly looks like

The outlook depends on the size of the tumour, the grade, the location, and the completeness of surgery.

• For localised disease treated with combined surgery, radiation, and chemotherapy, five-year survival is typically around 50–65% — and considerably higher for small tumours treated early.
• For small tumours (less than 5 cm) completely removed at presentation, the long-term outlook is the best — many patients are cured.
• For large or metastatic disease, the outlook is more difficult, but synovial sarcoma's chemosensitivity, and now the availability of engineered T-cell therapy, mean that long-term disease control is possible for a meaningful proportion of patients.

Numbers are averages — they do not predict any individual's outcome. The specific situation of each patient — age, fitness, tumour biology, response to treatment — all matter. We will always be honest with you about the realistic range for your particular case.

Life during treatment

Treatment for synovial sarcoma is intensive but time-limited. A typical journey looks something like this:

• A few weeks for imaging, biopsy, and team review.
• Several months of chemotherapy, often before and after surgery — usually four to six cycles in total.
• Surgery — limb-sparing in the vast majority of cases — with recovery over several weeks, often with physiotherapy.
• A course of radiation, typically over five to six weeks.

Through all of it, most patients continue much of their normal life. Many young adults pause university or work for the most intense weeks and return afterwards. Hair loss from chemotherapy is temporary. Fertility is an important question to raise on day one — for both young men and young women, there are options to protect it, but they need to be arranged before chemotherapy starts.

After treatment — long-term lung surveillance

Because the lung is by far the most common site of recurrence, follow-up centres on the chest:

• Clinical review and examination of the primary site every 3 months for the first 2 years, then less often.
• MRI of the primary site at intervals decided by the team.
• CT scan of the chest every 3–6 months for the first 2 years, then 6-monthly to year 5, then yearly. Lung surveillance continues for at least 10 years, because synovial sarcoma can recur late.

If a small number of lung nodules do appear, they are often still treatable — sometimes with surgery, sometimes with stereotactic radiation, sometimes with systemic therapy. Long-term remissions after second-line treatment are well recognised in synovial sarcoma. Read about survivorship care →

The most important things to take away

• Synovial sarcoma is aggressive — but it is also one of the more chemosensitive soft-tissue sarcomas, and many people with localised disease are cured.
• A deep, painful lump in a young adult — especially near a joint — should be imaged, not "watched".
• The diagnosis is confirmed by molecular testing for the SS18-SSX fusion. Make sure that test is done.
• Treatment is multimodal — surgery, radiation, and chemotherapy — and is best delivered by a sarcoma team.
• Even for advanced disease, the options keep growing. Engineered T-cell therapy is a recent and meaningful breakthrough.